Pliant Therapeutics, Inc. (PLRX) Stock Price & Analysis
Pliant Therapeutics, Inc. (PLRX) rose 3.48% to USD 1.19 as of June 10, 2026 at 03:15 UTC, according to Nexqual real-time market data.
PLRX last closed at USD 1.15; the session ranged USD 1.13–1.2 on volume of 279,742 shares. Market capitalization is $73.69M, with a 52-week range of USD 1.09–1.95 (NMS). Source: Nexqual, June 10, 2026 at 03:15 UTC.
Key Statistics (as of June 10, 2026 at 03:15 UTC)
| Price | USD 1.19 |
|---|---|
| Change | ▲ 3.48% (up) |
| Previous Close | USD 1.15 |
| Open | USD 1.16 |
| Day Range | USD 1.13 – 1.2 |
| 52-Week Range | USD 1.09 – 1.95 |
| Volume | 279,742 shares |
| Market Cap | $73.69M |
| Exchange | NMS |
Technical Analysis (PLRX)
Nexqual's technical model rates PLRX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:15 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.9 (neutral) |
| vs SMA50 | Below (USD 1.24) |
| MACD | -0.02 (negative) |
Analyst Ratings (PLRX)
Wall Street analysts rate PLRX "None" based on 3 analysts, with a mean price target of USD 2.67 (range USD 2–3), per Nexqual as of June 10, 2026 at 03:15 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 2.67 |
| High Target | USD 3 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 1 / 4 / 1 |
Earnings (PLRX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.35 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.32 vs est -0.36 ▲ beat |
| 2025-12-31 | USD -0.35 vs est -0.38 ▲ beat |
| 2025-09-30 | USD -0.43 vs est -0.52 ▲ beat |
| 2025-06-30 | USD -0.71 vs est -0.68 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:15 UTC.
Financials & Fundamentals (PLRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -53.62% |
| Debt / Equity | 17.43 |
| Current Ratio | 16.89 |
| Total Cash | $170.89M |
| Total Debt | $28.78M |
| Free Cash Flow | $-61.81M |
Source: Nexqual, June 10, 2026 at 03:15 UTC.
Financial Health Score (PLRX)
Nexqual rates Pliant Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:15 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $171M cash vs $29M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$99M |
| Efficiency | Critical — ROE -54%, ROA -25.8% |
Ownership (PLRX)
| Insider Ownership | +2.35% |
|---|---|
| Institutional Ownership | +81.95% |
| Shares Outstanding | 61.92M |
| Float | 60.23M |
| Short % of Float | +5.68% |
Source: Nexqual, June 10, 2026 at 03:15 UTC.
Leadership (PLRX)
Pliant Therapeutics, Inc. is led by Bernard Coulie M.B.A. (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:15 UTC.
| President, CEO & Director | Bernard Coulie M.B.A. (age 59) |
|---|---|
| Chief Financial Officer | Keith Lamont Cummings (age 48) |
| Chief Operating Officer | Minnie Kuo (age 44) |
| Vice President of Investor Relations & Corporate Communications | Christopher S. Keenan |
| Vice President, Regulatory & Compliance | Monica Sandberg |
Major Backers & Investors (PLRX)
Notable institutional backers of Pliant Therapeutics, Inc. include Tang Capital Management, LLC, Citadel, Blue Owl Capital Holdings LP, according to Nexqual as of June 10, 2026 at 03:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Tang Capital Management, LLC | 9.92% |
| Citadel | 5.21% |
| Blue Owl Capital Holdings LP | 4.8% |
| Adar1 Capital Management, LLC | 4.17% |
| Acadian Asset Management. LLC | 3.9% |
| Two Sigma Investments, LP | 3.64% |
| Monaco Asset Management SAM | 3.13% |
| Renaissance Technologies | 2.99% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.69% |
Source: Nexqual, June 10, 2026 at 03:15 UTC.
From Pliant Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.
- The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
- It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NKTX | Nkarta, Inc. | USD 2.45 | ▼ 2.39% |
| PASG | Passage Bio, Inc. | USD 5.57 | ▼ 0.89% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| STOK | Stoke Therapeutics, Inc. | USD 29.37 | ▼ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:15 UTC. This page is informational and not investment advice.